NCT06389552 Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
| NCT ID | NCT06389552 |
| Status | Recruiting |
| Phase | — |
| Sponsor | HK inno.N Corporation |
| Condition | Adjuvant Chemotherapy |
| Study Type | OBSERVATIONAL |
| Enrollment | 36 participants |
| Start Date | 2023-09-25 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 36 participants in total. It began in 2023-09-25 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
Eligibility Criteria
Inclusion Criteria: * Age over 19 at the time of obtaining the informed consent form * Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery * ECOG 0 or 1 * Scheduled to RO or R1 resection * Organ function capable of chemotherapy Exclusion Criteria: * FOLFIRINOX contraindications among the drug approval requirements * Palliative Therapy * Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
Contact & Investigator
Myung-Ah Lee
STUDY CHAIR
Seoul St. Mary's Hospital
Frequently Asked Questions
Who can join the NCT06389552 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Adjuvant Chemotherapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06389552 currently recruiting?
Yes, NCT06389552 is actively recruiting participants. Contact the research team at soyeon.ahn@inno-n.com for enrollment information.
Where is the NCT06389552 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06389552 clinical trial?
NCT06389552 is sponsored by HK inno.N Corporation. The principal investigator is Myung-Ah Lee at Seoul St. Mary's Hospital. The trial plans to enroll 36 participants.